Autonomix Medical, Inc. announced on January 17, 2025, that it has finalized the design, achieving 'design lock,' for its Application Specific Integrated Circuits (ASIC) microchip. This milestone follows successful in vivo preclinical testing and extensive bench testing.
The ASIC microchip is a core component of Autonomix's intellectual property portfolio, enabling its catheter-based sensing array to detect and differentiate small amplitude nerve signals through the vasculature. Manufacturing of this ASIC microchip for targeted use in humans has now been initiated.
This technical achievement is a significant step towards commencing a pivotal clinical trial in the United States, planned for 2025. The company expects these advancements to support a labeling indication for commercializing the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.